Blog
RSS FeedPosted by Michael Wonder on 12 Dec 2024
ICER announces most significant drug price hikes unsupported by new clinical evidence in US
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...
Posted by Michael Wonder on 12 Dec 2024
Outcome statements for October 2024 stakeholder meetings: oral contraceptives and migraine
9 December 2024 - The Outcome Statements are now available for the Oral Contraceptives Stakeholder Meeting held on 10 October 2024 ...
Posted by Michael Wonder on 01 Dec 2024
DUSC utilisation analysis public release documents (June 2024) update
22 November 2024 - The utilisation analysis public release documents from the June 2024 DUSC meeting are now available. ...
Posted by Michael Wonder on 16 Nov 2024
Outcome statement - October 2024 DUSC meeting
15 November 2024 - The outcome statement from the October 2024 DUSC meeting is now available. ...
Posted by Michael Wonder on 15 Nov 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - July 2024 PBAC meeting
15 November 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2024 PBAC ...
Posted by Michael Wonder on 01 Nov 2024
Public Summary Documents – July 2024 PBAC meeting
1 November 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2024 PBAC ...
Posted by Michael Wonder on 01 Nov 2024
ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...
Posted by Michael Wonder on 01 Oct 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - May 2024 PBAC meeting
1 October 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the May 2024 PBAC ...
Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 11 Sep 2024
Final reports of the HTA Policy and Methods Review and Enhanced Consumer Engagement Process
10 September 2024 - The reports of the HTA Review and the Enhanced Consumer Engagement Process have been published. ...
Posted by Michael Wonder on 06 Sep 2024
ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
Posted by Michael Wonder on 30 Aug 2024
Public Summary Documents – May 2024 PBAC meeting
30 August 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2024 PBAC ...
Posted by Michael Wonder on 19 Jul 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - March 2024 PBAC meeting
19 July 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2024 ...
Posted by Michael Wonder on 19 Jul 2024
DUSC utilisation analysis public release documents (June 2024)
19 July 2024 - The utilisation analysis public release documents from the June 2024 DUSC meeting are now available. ...
Posted by Michael Wonder on 19 Jul 2024
Outcome statement - June 2024 DUSC meeting
19 July 2024 - The outcome statement from the June 2024 DUSC meeting is now available. ...